FDA Adds Temporary Expertise To ODAC For Filgrastim Biosimilar Meeting

NIH researcher of cellular therapy manufacturing, experts in pharmacology and pharmaceutical sciences join Oncologic Drugs Advisory Committee for consideration of FDA’s first 351(k) application.